An international team led by UBC researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts. The findings hold promise as a treatment capable of stopping early infection of the novel coronavirus.
We are hopeful our results have implications for the development of a novel drug for the treatment of this unprecedented pandemic, says Penninger, professor in UBCs faculty of medicine, director of the Life Sciences Institute and the Canada 150 Research Chair in Functional Genetics at UBC….
